Showing results (131-140 of 900) with videos related to

Sort By:
Pageof 90
Leukemia & Lymphoma|October 10, 2009
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategyDeborah A Thomas, Farhad Ravandi, Michael Keating, et al.
Expert Review of Hematology|November 25, 2010
Acute erythroleukemia: diagnosis and managementFabio P S Santos, Carlos E Bueso-Ramos, Farhad Ravandi
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2013
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemiaKumudha Balakrishnan, Farhad Ravandi, Shanta Bantia, et al.
Cancer|December 31, 2015
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapyLorenzo Falchi, Srdan Verstovsek, Farhad Ravandi-Kashani, et al.
Biologics : Targets & Therapy|February 28, 2020
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted ImmunotherapyMiguel J Franquiz, Nicholas J Short
The Oncologist|December 10, 2013
New oral anticoagulants and the cancer patientNicholas J Short, Jean M Connors
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?Fadi G Haddad, Nicholas J Short
Haematologica|July 23, 2026
Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remissionEitan Kugler, Farhad Ravandi, Alex Bazinet, et al.
Frontiers in Oncology|November 16, 2020
Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
Pageof 90